Enanta Pharmaceuticals Inc. Common Stock (ENTA)
Stock · NASDAQ · Health Care
$11.11as of 10/16/2026
Price chart
Active signals
ENTA Signal Track Record
How signals performed across all stocks →What ENTA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -3.3% | 45% | October 2, 2026 |
| Bollinger Band BreakdownActive now | 21 | -1.8% | 43% | September 15, 2026 |
| Bollinger Band Breakout | 22 | +2.6% | 55% | May 6, 2026 |
| 200-Day Moving Average TouchActive now | 19 | -1.7% | 42% | September 1, 2026 |
| Any 20-session window (baseline) | -2.4% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; E…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 120
- Website
- www.enanta.com/
Fundamentals
- 1-day range
- $10.95$11.62
- Market cap
- $387.91M
- P/E (trailing)
- —
- P/E (forward)
- -4.68
- EPS (trailing)
- $-2.41
- Dividend yield
- —
- Beta
- 0.72
- Avg. volume
- 231.1K
How Enanta Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Nov 19, 2025 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Enanta Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ENTAEnanta Pharmaceuticals Inc. Common Stock$11.1▼ 3.23%Market cap $387.91MP/E —$10.2$17.15
- RCKTRocket Pharmaceuticals Inc. Common Stock$2.18▼ 7.63%Market cap $386.55MP/E —$2.42$5.45
- ABEOAbeona Therapeutics Inc. Common Stock$4.43▼ 4.73%Market cap $393.27MP/E 5.50$4$7.65
- AVIRAtea Pharmaceuticals Inc. Common Stock$4.32▼ 4.64%Market cap $399.34MP/E —$2.87$6.45
- UPBUpstream Bio Inc. Common Stock$2.76▼ 18.10%Market cap $373.87MP/E —$3.29$33.68
- PRLDPrelude Therapeutics Incorporated Common Stock$3.26▼ 1.81%Market cap $372.74MP/E —$1.16$6.83
- DMACDiaMedica Therapeutics Inc. Common Stock$7.57▼ 5.85%Market cap $364.79MP/E —$5.25$10.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals Inc. Common Stock | $387.91M | — | $11.1 | ▼ 3.23% | $10.2$17.15 |
| RCKT Rocket Pharmaceuticals Inc. Common Stock | $386.55M | — | $2.18 | ▼ 7.63% | $2.42$5.45 |
| ABEO Abeona Therapeutics Inc. Common Stock | $393.27M | 5.50 | $4.43 | ▼ 4.73% | $4$7.65 |
| AVIR Atea Pharmaceuticals Inc. Common Stock | $399.34M | — | $4.32 | ▼ 4.64% | $2.87$6.45 |
| UPB Upstream Bio Inc. Common Stock | $373.87M | — | $2.76 | ▼ 18.10% | $3.29$33.68 |
| PRLD Prelude Therapeutics Incorporated Common Stock | $372.74M | — | $3.26 | ▼ 1.81% | $1.16$6.83 |
| DMAC DiaMedica Therapeutics Inc. Common Stock | $364.79M | — | $7.57 | ▼ 5.85% | $5.25$10.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price TargetBenzinga · 9/23/2026
Insider Activity
Insider Actions →- Scott T. Rottinghaus · August 8, 2026 · Tax Withholding1.5K @ $13.34
Institutional Ownership
March 31, 2026
- Total shares held
- 25.57M
- Total value held
- $275.17M
- Institutional holders
- 128
- Unknown3.78M
- Unknown3.10M
- Unknown2.87M
- Unknown2.87M
- Unknown1.96M
- Unknown1.18M
- Unknown932.6K
- Unknown882.1K
- Unknown880.0K
- Unknown725.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
HC Wainwright Maintains $20 Target for Enanta
HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.
HC Wainwright Maintains $20 Target for Enanta. HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.